108 related articles for article (PubMed ID: 2316090)
1. Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
Brausi M; Blatnik A; Soloway MS
Urology; 1990 Mar; 35(3):253-6. PubMed ID: 2316090
[TBL] [Abstract][Full Text] [Related]
2. Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Hickey DP; Brausi M; Blatnik AF; Soloway MS
Urology; 1987 Nov; 30(5):484-7. PubMed ID: 3118551
[TBL] [Abstract][Full Text] [Related]
3. Systemic chemotherapy of murine bladder cancer.
Soloway MS; Niell HB; Matheny RB; Blatnik A
Urology; 1984 Apr; 23(4 Suppl):129-34. PubMed ID: 6538713
[No Abstract] [Full Text] [Related]
4. Evaluation of chemotherapy in a murine model for bladder cancer.
Murphy GP; Pontes JE; Williams PD
Oncology; 1984; 41(3):195-9. PubMed ID: 6539460
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
6. A murine model for bladder cancer.
Murphy GP; Sandberg AA; Pontes JE; Ochi H; Yoshida M; Williams PD
Prog Clin Biol Res; 1984; 162A():177-200. PubMed ID: 6541340
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium.
Geertsen PF; Sengeløv L; Larsen SK; von der Maase H
Eur J Cancer; 1993; 29A(3):347-50. PubMed ID: 8398332
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Oh WK; Manola J; Richie JP; Loughlin KR; Kantoff PW
Cancer; 1999 Oct; 86(7):1329-34. PubMed ID: 10506721
[TBL] [Abstract][Full Text] [Related]
9. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
[No Abstract] [Full Text] [Related]
10. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
[TBL] [Abstract][Full Text] [Related]
11. Intravesical and systemic chemotherapy of murine bladder cancer.
Soloway MS
Cancer Res; 1977 Aug; 37(8 Pt 2):2918-29. PubMed ID: 406041
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of chemotherapeutic effects by recombinant human granulocyte colony-stimulating factor on implanted mouse bladder cancer cells (MBT-2).
Akaza H; Fukushima H; Koiso K; Aso Y
Cancer; 1992 Feb; 69(4):997-1002. PubMed ID: 1370920
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
15. Chemoimmunotherapy of murine bladder cancer.
Stogdill BJ; Lamm DL; Livingston RB
Invest Urol; 1981 Nov; 19(3):179-81. PubMed ID: 7298287
[TBL] [Abstract][Full Text] [Related]
16. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Borden EC; Sidky YA; Ertürk E; Wierenga W; Bryan GT
Cancer Res; 1990 Feb; 50(4):1071-4. PubMed ID: 2297754
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder.
Stoter G; Splinter TA; Child JA; Fosså SD; Denis L; van Oosterom AT; de Pauw M; Sylvester R
J Urol; 1987 Apr; 137(4):663-7. PubMed ID: 3560318
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
20. The effect of platinum analogues and combination chemotherapy on murine bladder cancer.
Soloway MS; Cox CE
Trans Am Assoc Genitourin Surg; 1979; 71():8-13. PubMed ID: 545820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
